370 related articles for article (PubMed ID: 12705679)
1. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
[TBL] [Abstract][Full Text] [Related]
2. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
3. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
[TBL] [Abstract][Full Text] [Related]
4. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
Heaton VJ; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
[TBL] [Abstract][Full Text] [Related]
5. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
6. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
7. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae.
Gillespie SH; Voelker LL; Dickens A
Microb Drug Resist; 2002; 8(2):79-84. PubMed ID: 12118521
[TBL] [Abstract][Full Text] [Related]
8. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Weigel LM; Anderson GJ; Facklam RR; Tenover FC
Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
[TBL] [Abstract][Full Text] [Related]
9. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
[TBL] [Abstract][Full Text] [Related]
10. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
12. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
[TBL] [Abstract][Full Text] [Related]
14. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
Tankovic J; Perichon B; Duval J; Courvalin P
Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
[TBL] [Abstract][Full Text] [Related]
15. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
16. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
[TBL] [Abstract][Full Text] [Related]
17. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
Varon E; Janoir C; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
[TBL] [Abstract][Full Text] [Related]
18. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
[TBL] [Abstract][Full Text] [Related]
19. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Azoulay-Dupuis E; Bédos JP; Mohler J; Peytavin G; Isturiz R; Moine P; Rieux V; Cherbuliez C; Péchère JC; Fantin B; Köhler T
Antimicrob Agents Chemother; 2004 Mar; 48(3):765-73. PubMed ID: 14982762
[TBL] [Abstract][Full Text] [Related]
20. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
